TERIFRAC 750MG/3ML INJ

Price 4400 INR/ Thousand

Get a Price/Quote

TERIFRAC 750MG/3ML INJ Specification

Indication
Treatment of osteoporosis in postmenopausal women and men at increased risk of fracture

Origin of Medicine
Biotechnology

Pacakaging (Quantity Per Box)
1 pre-filled pen per box

Dosage Form
Injection

Salt Composition
Teriparatide 750 mcg

Drug Type
Prescription Only Medication

Ingredients
Teriparatide

Physical Form
Injection

Function
Promotes new bone formation, increases bone mineral density, reduces fracture risk

Recommended For
Adults with osteoporosis at high risk of fracture

Dosage
750 mcg/3 ml (250 mcg/ml)

Dosage Guidelines
Administer as directed by the physician, typically 20 mcg once daily by subcutaneous injection.

Suitable For
Adults

Quantity
3 ml per pre-filled pen

Storage Instructions
Store in a refrigerator (2C 8C). Do not freeze.

Colour
Colourless to pale yellow

Therapeutic Class
Parathyroid hormone analogs

Caution
Use under medical supervision. Not recommended during pregnancy and lactation unless advised by a doctor.

Shelf Life
28 days after first use

Marketed By
Intas Pharmaceuticals Ltd.

Brand Name
TERIFRAC

Preservative Free
Yes

HSN Code
30049099

Route of Administration
Subcutaneous

MRP
As per current market rate

Availability
Hospital and retail pharmacies

About TERIFRAC 750MG/3ML INJ

Terifrac Injection is a man-made version of parathyroid hormone used to treat men and postmenopausal women who have severe osteoporosis with a high risk of fractures. It works by stimulating new bone formation, which improves bone density and decreases the risk of spinal fractures.Terifrac Injection should be injected under the skin or given by a healthcare professional. You should use it regularly and at the same time each day to get the maximum benefit from it. Usually, it is recommended to take it for a maximum period of 2 years. However, follow the doctors advice and complete the course even if you feel better. It should be stored in the refrigerator at a temperature of 2C to 8C.Some common side effects of this medicine include joint pain, injection site reactions (such as pain, swelling, and redness) and leg cramps. consult with your doctor if any of these bother you or do not go away.Before taking this medicine, let your doctor know if you have kidney stones or any other kidney problems, as it can cause an increase in the amount of calcium in blood or urine. Pregnant and breastfeeding mothers should also consult with their doctors before taking this medicine. Your doctor may advise a bone scan to monitor the progress of your treatment.

Promotes New Bone Formation

TERIFRAC, containing Teriparatide, works by stimulating the formation of new bone tissue. This action enhances bone mineral density, making the bones stronger and less prone to fractures, particularly in individuals with osteoporosis who are at heightened risk.

Tailored for High-Risk Osteoporosis Patients

Intended for both postmenopausal women and men experiencing osteoporosis with an increased risk of fractures, TERIFRAC offers a targeted solution under strict medical supervision. Its efficacy is backed by biotechnology and established therapeutic benefits.

Convenient and Controlled Administration

The pre-filled TERIFRAC pen allows for easy subcutaneous self-injection, usually once daily, as directed by your doctor. Its preservative-free formulation ensures safety, while the simple dosing mechanism supports adherence to therapy.

FAQ's of TERIFRAC 750MG/3ML INJ:

Q: How should TERIFRAC 750MG/3ML INJ be administered?

A: TERIFRAC is administered as a subcutaneous injection, typically once daily at a dose of 20 mcg, following your doctor's specific instructions. Use the pre-filled pen to inject into the thigh or abdomen, and rotate the injection site daily to minimize discomfort.

Q: What is the primary benefit of using TERIFRAC for osteoporosis?

A: TERIFRAC promotes the formation of new bone, increasing bone mineral density and reducing the risk of fractures in individuals with osteoporosis who are at high risk. This makes it a valuable therapy for strengthening fragile bones.

Q: When should TERIFRAC treatment be discontinued?

A: The duration of TERIFRAC therapy is determined by your physician, but it is typically limited to 24 months during a patient's lifetime. Do not stop or continue treatment without medical advice.

Q: Where should TERIFRAC be stored after first use?

A: After the first use, TERIFRAC should be kept in a refrigerator at 2C to 8C and must not be frozen. It should be discarded 28 days after initial use, even if some solution remains.

Q: What precautions should be taken during TERIFRAC treatment?

A: Use TERIFRAC strictly under medical supervision. It is not recommended during pregnancy or lactation unless prescribed by a doctor. Inform your healthcare provider of any other medications or health conditions before starting treatment.